OUR STORY

We dream of a world without dementia.

ADEL is a leading company of cutting-edge technologies for the treatment and diagnosis of Alzheimer's disease and other dementia.

Founded by a group of scientists who have investigated Alzheimer's disease at Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, today we are developing smart, innovative drug candidates for the patients worldwide.

Get in touch today to learn more about the ADEL story.

PIPELINES

ADEL-Y01

Tau antibody

ADEL-Y01 targets the pathologically modified epitope of Tau protein which is very important for Tau aggregation and propagation.
ADEL-Y01 has superior effects on inhibiting tau aggregation and propagation over company-X antibody which is in clinical trial.

ADEL-Y02

BBB-engineered ADEL-Y01

Engineered version of ADEL-Y01 to increase BBB penetration.

ADEL-Y03~05

Novel target-based antibodies and peptides

With strong biological backgrounds, we are validating novel therapeutic targets for Alzheimer's disease and developing the bio-drugs of these targets.

OPEN POSITIONS 채용 공고

We’re Hiring

As a growing Biotechnology Startup Company, we are always looking for new team members. Whether you’re interested in business or have something innovative and unique to bring to the table, we’d love to see if you’re a good fit for ADEL. Send us your CV today to and we will get back to you as soon as we can.